mRNA 疫苗在实体器官移植受者中的单剂免疫原性。
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.
机构信息
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
出版信息
JAMA. 2021 May 4;325(17):1784-1786. doi: 10.1001/jama.2021.4385.
Abstract
This study quantifies antispike protein antibody responses to first-dose messenger RNA (mRNA) COVID-19 vaccines in solid organ transplant recipients to better understand the immunogenicity of the vaccines in immunocompromised individuals.
摘要
本研究定量分析了实体器官移植受者对信使 RNA（mRNA）COVID-19 疫苗首剂的抗刺突蛋白抗体反应，以更好地了解疫苗在免疫功能低下个体中的免疫原性。
相似文献
1
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.mRNA 疫苗在实体器官移植受者中的单剂免疫原性。
JAMA. 2021 May 4;325(17):1784-1786. doi: 10.1001/jama.2021.4385.
2
SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19.严重急性呼吸综合征冠状病毒2型信使核糖核酸疫苗在曾感染2019冠状病毒病的实体器官移植受者中的免疫原性
Transplantation. 2021 Nov 1;105(11):e270-e271. doi: 10.1097/TP.0000000000003900.
3
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.实体器官移植受者对两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗系列的抗体反应。
JAMA. 2021 Jun 1;325(21):2204-2206. doi: 10.1001/jama.2021.7489.
4
Poor Humoral Response in Solid Organ Transplant Recipients Following Complete mRNA SARS-CoV-2 Vaccination.实体器官移植受者完成mRNA SARS-CoV-2疫苗接种后体液免疫反应不佳。
Clin Chem. 2021 Dec 30;68(1):251-253. doi: 10.1093/clinchem/hvab149.
5
Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者中灭活 SARS-CoV-2 疫苗和 BNT162b2 mRNA 疫苗的抗体反应差异。
Exp Clin Transplant. 2021 Dec;19(12):1334-1340. doi: 10.6002/ect.2021.0402.
6
Antibody Response to the Janssen COVID-19 Vaccine in Solid Organ Transplant Recipients.实体器官移植受者对杨森新冠疫苗的抗体反应。
Transplantation. 2021 Aug 1;105(8):e82-e83. doi: 10.1097/TP.0000000000003850.
7
Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.肾移植受者同源与异源第三剂疫苗接种后 4 周时的 SARS-CoV-2 抗体反应比较：一项随机临床试验。
JAMA Intern Med. 2022 Feb 1;182(2):165-171. doi: 10.1001/jamainternmed.2021.7372.
8
Improved immunogenicity against SARS-CoV-2 in a solid-organ transplant recipient by switching vaccines.通过更换疫苗提高实体器官移植受者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的免疫原性。
Clin Microbiol Infect. 2021 Oct;27(10):1529-1530. doi: 10.1016/j.cmi.2021.06.022. Epub 2021 Jun 27.
9
SARS-CoV-2 anti-spike IgG antibodies are present in all liver transplant recipients after fifth vaccine dose.在接受第五剂疫苗后，所有肝移植受者体内均存在新冠病毒抗刺突IgG抗体。
J Hepatol. 2024 Jun;80(6):e284-e286. doi: 10.1016/j.jhep.2023.12.008. Epub 2023 Dec 16.
10
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者接种三剂mRNA新冠疫苗
N Engl J Med. 2021 Aug 12;385(7):661-662. doi: 10.1056/NEJMc2108861. Epub 2021 Jun 23.
引用本文的文献
1
Outcomes of SARS-CoV-2 infection in patients under treatment with pharmacological immunosuppression. A Swiss cohort study.接受药物免疫抑制治疗患者的新冠病毒感染结局。一项瑞士队列研究。
Arch Med Sci. 2022 Aug 3;21(3):845-851. doi: 10.5114/aoms/152340. eCollection 2025.
2
Post-COVID-19 cardiovascular disease risk in kidney transplant recipients.肾移植受者中新冠病毒感染康复后的心血管疾病风险
Am J Transplant. 2025 Jul 15. doi: 10.1016/j.ajt.2025.07.2462.
3
Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19.接受用于治疗COVID-19的奈玛特韦-利托那韦的肾移植受者的他克莫司优化给药策略
PLoS One. 2025 May 30;20(5):e0309875. doi: 10.1371/journal.pone.0309875. eCollection 2025.
4
Antibody Response to Covishield and Covaxin in Kidney Transplant Recipients.肾移植受者对Covishield和Covaxin的抗体反应。
Indian J Nephrol. 2025 Mar-Apr;35(2):277-282. doi: 10.25259/ijn_549_23. Epub 2024 Aug 1.
5
A third COVID-19 vaccine dose in kidney transplant recipients induces antibody response to vaccine and Omicron variants but shows limited Ig subclass switching.肾移植受者接种第三剂新冠病毒疫苗可诱导对疫苗和奥密克戎变异株的抗体反应，但免疫球蛋白亚类转换有限。
Microbiol Spectr. 2025 Mar 4;13(3):e0219024. doi: 10.1128/spectrum.02190-24. Epub 2025 Jan 31.
6
Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.AZD7442与SARS-CoV-2疫苗在极易感染SARS-CoV-2病毒的免疫抑制患者中的适应性临床试验（快速保护）：一项多中心、介入性开放标签、随机对照试验方案
BMJ Open. 2025 Jan 20;15(1):e084345. doi: 10.1136/bmjopen-2024-084345.
7
Antibody Response to SARS-CoV-2 Vaccines in Transplant Recipients and Hemodialysis Patients: Data from the Dominican Republic.移植受者和血液透析患者对SARS-CoV-2疫苗的抗体反应：来自多米尼加共和国的数据。
Vaccines (Basel). 2024 Nov 23;12(12):1312. doi: 10.3390/vaccines12121312.
8
Impact of Immunosuppressants and Vaccination on COVID-19 Outcomes in Autoimmune Patients and Solid Organ Transplant Recipients: A Nationwide Propensity Score-Matched Study.免疫抑制剂和疫苗接种对自身免疫性疾病患者及实体器官移植受者新冠病毒病结局的影响：一项全国性倾向评分匹配研究
Vaccines (Basel). 2024 Oct 18;12(10):1190. doi: 10.3390/vaccines12101190.
9
Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation.SARS-CoV-2 特异性记忆 B 细胞在增强免疫后促进实体器官移植免疫保护的作用。
Front Immunol. 2024 Oct 8;15:1463769. doi: 10.3389/fimmu.2024.1463769. eCollection 2024.
10
Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients.免疫调节剂治疗的银屑病患者对BNT162b2疫苗的抗体反应。
J Psoriasis Psoriatic Arthritis. 2022 Jan;7(1):24-28. doi: 10.1177/24755303211056059. Epub 2021 Nov 12.
Zotero 插件